SCHEMBL4190022

SCHEMBL4190022

Cn1c(=O)n(C)c2cc(C(=O)CCl)ccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.63
▸ ALDH1A1 P00352 6/20 0.63
▸ HSD17B10 Q99714 2/20 0.63
▸ BRD4 O60885 2/20 0.63
▸ BRPF1 P55201 2/20 0.63
▸ KDM4E B2RXH2 2/20 0.63
▸ GLA P06280 1/20 0.58
▸ HTT P42858 4/20 0.57
▸ LMNA P02545 1/20 0.57
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ RAB9A P51151 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NR0B1 P51843 1/20 0.47
▸ KDM2B Q8NHM5 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859467 0.83 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL4860594 0.81 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL27593085 0.80 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL1119999 0.79 SMN1; SMN2 (0.71) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL1422842 0.79 SMN1; SMN2 (0.71) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL5981648 0.78 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL23846427 0.77 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL31060459 0.77 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL29040367 0.75 MEN1 (0.67) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1
SCHEMBL7539164 0.75 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1HSD17B10BRD4BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119118925-B Preparation method and application of benzimidazole-2-ketone derivative 中国人民解放军陆军军医大学 2025-05-27 — — CN claimed
CN-119118925-A Preparation method and application of benzimidazole-2-ketone derivative 中国人民解放军陆军军医大学 2024-12-13 — — CN claimed
CN-119118925-B Preparation method and application of benzimidazole-2-ketone derivative 中国人民解放军陆军军医大学 2025-05-27 — — CN disclosed
CN-119118925-A Preparation method and application of benzimidazole-2-ketone derivative 中国人民解放军陆军军医大学 2024-12-13 — — CN disclosed
US-20090130165-A1 MIF Inhibitors CORTICAL PTY LTD 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090130165-A1 MIF Inhibitors MIF, MMP12, IL4 SMN1; SMN2 4311/4885ALDH1A1 780/4885HSD17B10 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback